FFO
LXRX icon

Fortitude Family Office’s Lexicon Pharmaceuticals LXRX Stock Holding History

Fortitude Family Office’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1K Hold
706
– – ﹤0.01% 1484
2025
Q4 		$812 Hold
706
– – ﹤0.01% 1539
2025
Q3 		$953 Hold
706
– – ﹤0.01% 1562
2025
Q2 		$668 Buy
+706
New +$457 ﹤0.01% 1674

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fortitude Family Office's LXRX Position: Q1 2026 in Review

Fortitude Family Office held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 706 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1484.

Fortitude Family Office first reported a position in LXRX in Q2 2025 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Fortitude Family Office held 706 shares of Lexicon Pharmaceuticals worth $1.1K as of Q1 2026.
  • Fortitude Family Office left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1484 holding.
  • Fortitude Family Office first reported a position in Lexicon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.